Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. BDB756520

CXCR5 (CD185) Rat anti-Human, RB545, BD OptiBuild™

Catalog No. BDB756520 Shop All BD Biosciences Products
Change view
Click to view available options
Quantity:
50 μg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
BDB756520 50 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. BDB756520 Supplier BD Biosciences Supplier No. 756520
Only null left
Add to Cart
Add to Cart

Description

Rat Primary Antibody

CXCR5 (CD185) Primary antibody specifically detects CXCR5 (CD185) in Human samples. It is validated for Flow Cytometry
TRUSTED_SUSTAINABILITY

Specifications

Antigen CXCR5 (CD185)
Applications Flow Cytometry
Clone RF8B2
Concentration 0.2 mg/mL
Conjugate RB545
Formulation Aqueous buffered solution containing ≤0.09% sodium azide.
Gene Alias CD185; Chemokine C-X-C motif receptor 5; BLR1; MDR-15
Host Species Rat
Immunogen Human CXCR5 (CD185)
Quantity 50 μg
Primary or Secondary Primary
Gene ID (Entrez) 643
Target Species Human
Content And Storage Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
Isotype IgG2b κ
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.